The Food and Drug Administration granted expanded approvals for two of Roche's cancer drugs this week.
The agency approved Roche's skin cancer drug Zelboraf in 2011 as a treatment for melanoma. The drug may now also be used to treat certain patients with Erdheim-Chester disease, a rare form of blood cancer. Zelboraf is the first FDA-approved treatment for this disease.
Roche's cancer drug Alecensa earned FDA approval in 2015 to treat patients with a rare form of non-small cell lung cancer who already received prior treatment with Pfizer's drug Xalkori. Now, Alecensa may also be used as an initial treatment for this patient population.
More articles on supply chain:
Amgen to lay off 200 research & development workers
Genentech to layoff 13% of workforce at California plant
Valeant sells $1B female libido unit back to original owners 2 years after acquisition